Vectus Biosystems Ltd
VBS
Company Profile
Business description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
Contact
26-34 Dunning Avenue
Unit 5, Ground Floor
Rosebery
SydneyNSW2018
AUST: +61 283441300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Bapcor earnings: Under review amid sharply lower profits and a massively dilutive equity raise
Our view of results.
stocks
Earnings winners: WOW, WTC and FMG set the tone
The ASX companies that closed out earnings season with a bang.
stocks
Do dividends build or limit wealth creation?
In this episode of Investing Compass, we talk to James Gruber about why he dislikes dividend stocks.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,422.20 | 13.50 | 0.14% |
| CAC 40 | 8,620.93 | 61.86 | 0.72% |
| DAX 40 | 25,289.02 | 113.08 | 0.45% |
| Dow JONES (US) | 49,499.20 | 17.05 | 0.03% |
| FTSE 100 | 10,846.70 | 40.29 | 0.37% |
| HKSE | 26,563.02 | 182.00 | 0.69% |
| NASDAQ | 22,878.38 | 273.69 | -1.18% |
| Nikkei 225 | 58,640.25 | 113.14 | -0.19% |
| NZX 50 Index | 13,682.46 | 11.75 | 0.09% |
| S&P 500 | 6,908.86 | 37.27 | -0.54% |
| S&P/ASX 200 | 9,184.30 | 9.00 | 0.10% |
| SSE Composite Index | 4,139.53 | 7.10 | -0.17% |